Link: Helix BioMedix Announces U.S. Patent Issuance for Novel Class of Antimicrobial – MarketWatch.
Helix BioMedix, Inc. (HXBM:
helix biomedix inc com new
News, chart, profile, more
Last: 0.53+0.12+29.27%
9:44am 08/07/2008
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
HXBM 0.53, +0.12, +29.3%) , a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,407,940 by the United States Patent and Trademark Office, which includes the company’s lead pre-clinical lipohexapeptide candidates.
The patent covers a family of hexapeptide antimicrobial agents, including HB1345, for use as broad spectrum topical anti-infectives. HB1345 will be developed initially for dermatological indications such acne, rosacea and atopic dermatitis. Subsequent clinical applications are anticipated to include prevention of hospital acquired infections, such as those caused by MRSA and other multi-resistant pathogens.
{ 1 comment… read it below or add one }
They actually have quite a big thing going on in their labs.